Clinical features, Treatment and Prognosis Analysis of T-cell non-Hodgkin's Lymphoma
DOI:
https://doi.org/10.58195/amr.v1i1.12Keywords:
T-cell, non-Hodgkin's lymphoma, clinical features, treatment, prognostic analysisAbstract
Objective: Regarding T-cell non-Hodgkin's lymphoma, it is important to explore both its clinical characteristics and treatment methods, as well as to make a good prognostic analysis. Methods: From 2017.02 to 2022.02, 40 patients with T-cell non-Hodgkin's lymphoma were seen in our hospital, and their data were implemented retrospectively. RESULTS: According to certain indicators of patients, they were divided into low-risk group (0-1 factors), low-medium-risk group (2 factors), high-medium-risk group (3 factors), and high-risk group (4-5 factors); after first-line treatment, the 3-year overall survival rates of patients with CR, PR, SD, and PD were 71%, 46%, 0%, and 0%, respectively; after treatment with CHOP-like regimens and other chemotherapy regimens, CR, PR, SD, and PD patients had 5-year overall survival rates of 44%, 36%, 0%, and 0%, respectively; after first-line treatment, CR patients were 16, PR patients were 16, and the effective rate was 80%, and SD+PD was 8. The CHOP-like regimen was used to treat 9 patients with CR, 9 patients with PR, 6 patients with SD, and 4 patients with PD; other chemotherapy regimens were used to treat 2 patients with CR, 4 patients with PR, 3 patients with SD, and 3 patients with PD, with an efficiency rate of 60% and an inefficiency rate of 40%. Conclusion: T-cell non-Hodgkin's lymphoma is easy to be misdiagnosed, and the prognosis analysis should be explored according to its clinical characteristics, combined with the treatment regimen, in order to ensure a significant treatment effect.
References
[1] Wei S. T. Expression of serum superoxide dismutase and its clinical significance in patients with non-Hodgkin’s lymphoma[D]. Ningxia Medical University, 2017.12.
[2] Wang Kun. Clinical characteristics and prognosis analysis of B-cell non-Hodgkin’s lymphoma with abnormal leukocyte count[D]. Shanxi Medical University, 2018.02.
[3] Liu ZJ. Prognostic analysis of primary colorectal non-Hodgkin’s lymphoma[D]. Jinan University, 2018.12.
[4] Wang Q. Exploration of prognostic factors in Chinese patients with Hodgkin’s lymphoma[D]. Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing. 2017.012.
[5] Sui Songnan.Basic and clinical studies of CD19-CAR-T cells for the treatment of B-cell non-Hodgkin’s lymphoma[D]. Tianjin Medical University, 2018.02.
[6] Deng X.W. Treatment and prognosis of peripheral T-cell lymphoma[D]. Chinese Academy of Medical Sciences, Peking Union Medical College, 2017.02.
[7] Wang Liao. p57KIP2 gene methylation status and clinical significance in patients with B-cell non-Hodgkin’s lymphoma[D]. Shanxi Medical University, 2017.12.
[8] Zhao Jiali.Analysis of factors associated with the occurrence of interstitial pneumonia after treatment of B-cell non-Hodgkin’s lymphoma[D]. Guangzhou Medical University, 2017.04.
[9] Wu Yan,Wang Hui,Liu Xiaojuan,et al.Analysis of 15-year clinical characteristics and treatment prognosis of 66 cases of condylomatous lymphoma[J]. Chinese Journal of Experimental Hematology, 2017,25(4):1036-1041.
[10] Zou Shengqin,Gu Qingjia. Clinical characteristics and treatment and prognosis analysis of head and neck non-Hodgkin’s lymphoma[J]. Journal of Chengdu Medical College, 2012,07(2):262-263.
[11] Rao Yanqiong,Guo Xia,Wan Zhi,et al. Clinical characteristics and prognosis analysis of mature B-cell non-Hodgkin’s lymphoma in children[J]. Chinese Journal of Maternal and Child Clinical Medicine (Electronic Version), 2020,16(1):81-92.
[12] Cheng Primghuang, Zhang Xiaoli, Ye Xian, et al. Clinical characteristics and prognosis analysis of 53 cases of non-Hodgkin’s lymphoma[J]. Journal of Soochow University (Medical Edition), 2012,32(4):566-567,584.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Qiaojiajie Zhao, Yudi Miao
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommerical-NoDerivatives 4.0 International License.